The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 95 (high attention) · dilution pressure high · listing risk high · governance risk low · runway 0.8 mo · strongest signal: MVLS deficiency (Sep 17, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (negative equity, runway < 6 months) coexists with live selling machinery (offering (424b)). Base case is a discounted raise; the question is when, not if.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
On September 17, 2026, Stardust Power (SDST) disclosed in an 8-K that it received notice from Nasdaq's Hearings Panel regarding Market Value of Listed Securities (MVLS) and minimum bid price deficiencies, explicitly referencing delisting risk. The next day, the company filed its 27th 424B5 prospectus supplement in the past twelve months, continuing an active at-the-market equity offering program. As of June 30, 2026 (the most recent balance sheet, now 80 days stale), the company held $540,264 in cash against $14.93 million in current liabilities, yielding an estimated 0.8 months of runway based on annualized operating cash outflows of $8.1 million.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 84 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Sep 18, 2026 | ▼ Offering (424B) | 424B5 prospectus supplement 2026-09-18; 26 prior 424B filings in 12m filing | 49 |
| Sep 17, 2026 | ▼ MVLS deficiency | “mvls deficiency” language in 8-K (8-K) filed 2026-09-17 filing | 63 |
| Sep 17, 2026 | ▼ Hearings panel | “hearings panel” language in 8-K (8-K) filed 2026-09-17 filing | 58 |
| Sep 17, 2026 | ▼ Exchange deficiency notice | 8-K Item 3.01 filed 2026-09-17 (accepted 17:00 ET) filing | 48 |
| Sep 17, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (8-K) filed 2026-09-17 filing | 48 |
| Sep 17, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (8-K) filed 2026-09-17 filing | 47 |
| Sep 17, 2026 | ▼ Reverse split | “reverse split” language in 8-K (8-K) filed 2026-09-17 filing | 35 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~0.8 months runway: liquidity $569,066 (cash $540,264 + investments $28,802) as of 2026-06-30, burn $8,116,489/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 44 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 10,579,727 (2026-05-13) -> 14,049,388 (2026-08-12), +33% filing | 35 |
| Jun 30, 2026 | ▼ Negative equity | Stockholders' equity $-8,240,860 as of 2026-06-30 filing | 31 |
| Jun 30, 2026 | ▼ Cash < current liabilities | Liquidity $569,066 vs current liabilities $14,930,120 filing | 22 |
GOVX GeoVax Labs, Inc. · MYSZ My Size, Inc. · SNTI Senti Biosciences Holdings, · GCTK Glucotrack, Inc. · SOAR Volato Group, Inc. · JUNS JUPITER NEUROSCIENCES, INC. · screener →